Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Bayer
Onyx Therapeutics, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Rebecca Miksad, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00813293
First received: December 22, 2008
Last updated: March 24, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)